KEDRAB
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- Brand name
- KEDRAB
- Generic name
- HUMAN RABIES VIRUS IMMUNE GLOBULIN
- Manufacturer
- Kedrion Biopharma Inc.
- Product type
- PLASMA DERIVATIVE
- SPL set ID
- 53f2a23b-c479-4c24-8cab-ee7a33a2633e
- SPL ID
- 11e6b9cf-25e9-7a79-e063-6394a90a9432
- Version
- 7
- Effective date
- 2024-02-21
- Source export date
- 2026-11-13
- Source partition
- 7
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0007-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-11-13/875ce92e4370b2000cf566c8a9c0e4d02cceccd3a3b18a8b0b87928b28506f0b/drug-label-0007-of-0014.json.zip
- Source manifest SHA-256
- 8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
- Import run
- 20261116T150851Z
- Imported at
- 2026-11-16 16:35:17
| Harmonized routes |
|---|
| INTRAMUSCULAR |
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| application applno | BLA | 125613 | derived:openfda.application_number |
| application number | BLA125613 | openfda.application_number | |
| brand name | KEDRAB | openfda.brand_name | |
| generic name | HUMAN RABIES VIRUS IMMUNE GLOBULIN | openfda.generic_name | |
| manufacturer name | Kedrion Biopharma Inc. | openfda.manufacturer_name | |
| ndc | package | 76125-150-10 | openfda.package_ndc |
| ndc | package | 76125-150-03 | openfda.package_ndc |
| ndc | package | 76125-150-02 | openfda.package_ndc |
| ndc | package | 76125-150-11 | openfda.package_ndc |
| ndc | product | 76125-150 | openfda.product_ndc |
| ndc11 | package | 76125015002 | derived:openfda.package_ndc |
| ndc11 | package | 76125015010 | derived:openfda.package_ndc |
| ndc11 | package | 76125015011 | derived:openfda.package_ndc |
| ndc11 | package | 76125015003 | derived:openfda.package_ndc |
| rxcui | 1992536 | openfda.rxcui | |
| rxcui | 1652833 | openfda.rxcui | |
| rxcui | 1992538 | openfda.rxcui | |
| rxcui | 1652827 | openfda.rxcui | |
| spl id | 11e6b9cf-25e9-7a79-e063-6394a90a9432 | id | |
| spl set id | 53f2a23b-c479-4c24-8cab-ee7a33a2633e | set_id | |
| unii | 95F619ATQ2 | openfda.unii |
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
5 WARNINGS AND PRECAUTIONS Do not give KEDRAB to persons who have completed rabies pre- or post-exposure prophylaxis because it can interfere with the anamnestic response to the rabies vaccine. ( 5.1 ) Hypersensitivity reactions, including anaphylaxis, may occur with KEDRAB. IgA deficient patients with antibodies against IgA are at greater risk. Have epinephrine available immediately to treat any acute severe hypersensitivity reactions. ( 5.2 ) Interference with live attenuated virus vaccines. ( 5.5 , 7 ) KEDRAB is made from human plasma, and may carry a risk of transmitting infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and theoretically, the Creutzfeldt-Jakob disease (CJD) agent. ( 5.7 ) 5.1 Previous Rabies Vaccination Patients who can document previous complete rabies pre-exposure prophylaxis or complete post-exposure prophylaxis should only receive a booster rabies vaccine without KEDRAB because KEDRAB may interfere with the anamnestic response to the vaccine (ACIP) 1 . 5.2 Hypersensitivity Reactions Hypersensitivity reactions, including anaphylaxis, may occur with KEDRAB. History of prior systemic allergic reactions to human immunoglobulin preparations places patients at greater risk. Have epinephrine available for treatment of acute allergic symptoms. Patients with isolated immunoglobulin A (IgA) deficiency may develop severe hypersensitivity reactions to KEDRAB or, subsequently, to the administration of blood products that contain IgA. 5.5 Live Attenuated Virus Vaccines KEDRAB administration may interfere with the development of an immune response to live attenuated virus vaccines. If feasible, delay immunization with measles vaccine for 4 months, and other live attenuated virus vaccines for 3 months, after KEDRAB administration. 5.6 Interference with Serologic Testing A transient rise of the various passively transferred antibodies in the patient's blood may result in misleading positive results of serologic tests after KEDRAB administration. Passive transmission of antibodies to erythrocyte antigens, e.g., A, B, and D, may interfere with serologic tests for red cell antibodies such as the antiglobulin test (Coombs' test). 5.7 Transmissible Infectious Agents Because KEDRAB is made from human plasma donors hyper-immunized with rabies vaccine, it may carry a risk of transmitting infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. All infections suspected by a physician possibly to have been transmitted by this product should be reported by the physician or other healthcare provider to Kedrion Biopharma Inc. at 1-855-353-7466.
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
6 ADVERSE REACTIONS The most common adverse reactions (>5%) observed in adult subjects were injection site pain, headache, muscle pain, joint pain, dizziness, and fatigue. The most common adverse reactions (>5%) observed in pediatric patients were injection site pain, headache, pyrexia, plain in extremity, bruising, fatigue and vomiting. The most common adverse reactions (>5%) observed in adult subjects were injection site pain, headache, muscle pain, joint pain, dizziness, and fatigue. The most common adverse reactions (>5%) observed in pediatric patients were injection site pain, headache, pyrexia, plain in extremity, bruising, fatigue, and vomiting. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Kedrion Biopharma Inc. at 1-855-353-7466 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of a drug cannot be directly compared to rates of adverse reactions in clinical trials of another drug and may not reflect the rates observed in clinical practice. KEDRAB was evaluated in three single-center, controlled clinical trials in adults. Subjects in these clinical studies of KEDRAB were healthy adults, primarily white, and ranged in age from 18 to 72 years. A total of 160 adult subjects were treated in these three studies, including 91 subjects who received single intramuscular doses of KEDRAB (20 IU/kg) with or without rabies vaccine. Table 2 summarizes adverse reactions occurring in >3% of adult subjects in the clinical trials of KEDRAB. ( Table 2 ). Table 2: Adverse Reactions Occurring in >3% of Subjects in All Combined Studies in Adults Data are presented as number of subjects (% of subjects). All KEDRAB (N=91) All Comparator HRIG (N=84) Saline Placebo+Vaccine (N=8) Injection site pain 30 (33%) 26 (31%) 2 (25%) Headache 14 (15%) 11 (13%) 3 (38%) Muscle pain 8 (9%) 6 (7%) 0 (0%) Joint Pain 5 (6%) 0 (0%) 1 (13%) Dizziness 5 (6%) 3 (4%) 0 (0%) Fatigue 5 (6%) 2 (2%) 0 (0%) Abdominal pain 4 (4%) 1 (1%) 0 (0%) Blood in urine (Hematuria) 4 (4%) 2 (2%) 0 (0%) Nausea 4 (4%) 3 (4%) 0 (0%) Feeling faint 4 (4%) 1 (1%) 0 (0%) Less frequent adverse reactions (≤3%) in adult subjects were diarrhea, vomiting, decreased appetite, musculoskeletal stiffness, malaise, weakness (asthenia), fainting (syncope), itching (pruritis), tingling sensation (paresthesia), rash, sunburn and elevation in liver function. KEDRAB was also evaluated in a two-center, open-label clinical trial in 30 pediatric patients exposed or possibly exposed to rabies virus. They ranged in age from 0.5 to 14.9 years. Study treatment included a single dose of KEDRAB (20 IU/kg) and active rabies vaccine on Days 0, 3, 7 and 14 administered as per ACIP 1 recommendations for rabies post-exposure prophylaxis. Twelve pediatric patients (40%) experienced adverse reactions within 14 days of receipt of KEDRAB and first dose of rabies vaccine. There were no serious adverse reactions. Table 3 summarizes the adverse reactions that occurred in >5% of patients in the pediatric clinical trial within 14 days of receipt of KEDRAB and the first dose of the rabies vaccine. Table 3: Adverse Reactions Occurring in >5% of Pediatric Patients within 14 Days of Post-exposure Prophylaxis with KEDRAB and Active Rabies Vaccine Data are presented as number of patients (% of patients). KEDRAB + Rabies Vaccine N = 30 Injection site pain 8 (27%) Headache 4 (13%) Fever (Pyrexia) 4 (13%) Pain in extremity 3 (10%) Bruising (hematoma) 2 (7%) Fatigue 2 (7%) Vomiting 2 (7%) Less common adverse reactions (≤5%) in pediatric patients were injection site redness (erythema), injection site swelling (edema), muscle pain, oral pain, and wound complication. Insomnia was reported as a less common adverse reactions (<5%) in pediatric patients occurring after 14 days of administration.
adverse reactions table
<table ID="t2" width="100%"><caption>Table 2: Adverse Reactions Occurring in >3% of Subjects in All Combined Studies in Adults</caption><col width="20.125%" align="left"/><col width="27.950%" align="left"/><col width="27.950%" align="left"/><col width="23.975%" align="left"/><tfoot><tr><td colspan="4" align="left" valign="top"><content/><paragraph styleCode="footnote">Data are presented as number of subjects (% of subjects).</paragraph></td></tr></tfoot><tbody><tr><td align="left" styleCode="Toprule Botrule Lrule Rrule" valign="bottom"><content/></td><td align="center" styleCode="Toprule Botrule Rrule" valign="bottom">All KEDRAB <content styleCode="bold">(N=91)</content></td><td align="center" styleCode="Toprule Botrule Rrule" valign="bottom">All Comparator HRIG <content styleCode="bold">(N=84)</content></td><td align="center" styleCode="Toprule Botrule Rrule" valign="bottom">Saline Placebo+Vaccine <content styleCode="bold">(N=8)</content></td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule" valign="top"><content/>Injection site pain </td><td align="center" styleCode="Botrule Rrule" valign="top">30 (33%)</td><td align="center" styleCode="Botrule Rrule" valign="top">26 (31%)</td><td align="center" styleCode="Botrule Rrule" valign="top">2 (25%)</td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule" valign="top"><content/>Headache </td><td align="center" styleCode="Botrule Rrule" valign="top">14 (15%)</td><td align="center" styleCode="Botrule Rrule" valign="top">11 (13%)</td><td align="center" styleCode="Botrule Rrule" valign="top">3 (38%)</td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule" valign="top"><content/>Muscle pain </td><td align="center" styleCode="Botrule Rrule" valign="top">8 (9%)</td><td align="center" styleCode="Botrule Rrule" valign="top">6 (7%)</td><td align="center" styleCode="Botrule Rrule" valign="top">0 (0%)</td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule" valign="top"><content/>Joint Pain </td><td align="center" styleCode="Botrule Rrule" valign="top">5 (6%)</td><td align="center" styleCode="Botrule Rrule" valign="top">0 (0%)</td><td align="center" styleCode="Botrule Rrule" valign="top">1 (13%)</td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule" valign="top"><content/>Dizziness </td><td align="center" styleCode="Botrule Rrule" valign="top">5 (6%)</td><td align="center" styleCode="Botrule Rrule" valign="top">3 (4%)</td><td align="center" styleCode="Botrule Rrule" valign="top">0 (0%)</td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule" valign="top"><content/>Fatigue </td><td align="center" styleCode="Botrule Rrule" valign="top">5 (6%)</td><td align="center" styleCode="Botrule Rrule" valign="top">2 (2%)</td><td align="center" styleCode="Botrule Rrule" valign="top">0 (0%)</td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule" valign="top"><content/>Abdominal pain </td><td align="center" styleCode="Botrule Rrule" valign="top">4 (4%)</td><td align="center" styleCode="Botrule Rrule" valign="top">1 (1%)</td><td align="center" styleCode="Botrule Rrule" valign="top">0 (0%)</td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule" valign="top"><content/>Blood in urine (Hematuria) </td><td align="center" styleCode="Botrule Rrule" valign="top">4 (4%)</td><td align="center" styleCode="Botrule Rrule" valign="top">2 (2%)</td><td align="center" styleCode="Botrule Rrule" valign="top">0 (0%)</td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule" valign="top"><content/>Nausea </td><td align="center" styleCode="Botrule Rrule" valign="top">4 (4%)</td><td align="center" styleCode="Botrule Rrule" valign="top">3 (4%)</td><td align="center" styleCode="Botrule Rrule" valign="top">0 (0%)</td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule" valign="top"><content/>Feeling faint </td><td align="center" styleCode="Botrule Rrule" valign="top">4 (4%)</td><td align="center" styleCode="Botrule Rrule" valign="top">1 (1%)</td><td align="center" styleCode="Botrule Rrule" valign="top">0 (0%)</td></tr></tbody></table>
adverse reactions table
<table ID="t3" width="100%"><caption>Table 3: Adverse Reactions Occurring in >5% of Pediatric Patients within 14 Days of Post-exposure Prophylaxis with KEDRAB and Active Rabies Vaccine</caption><col width="56.800%" align="left"/><col width="43.200%" align="left"/><tfoot><tr><td colspan="2" align="left" valign="top"><content/><paragraph styleCode="footnote">Data are presented as number of patients (% of patients).</paragraph></td></tr></tfoot><tbody><tr><td align="left" styleCode="Toprule Botrule Lrule Rrule" valign="top"><content/></td><td align="center" styleCode="Toprule Botrule Rrule" valign="top"><content styleCode="bold">KEDRAB + Rabies Vaccine</content> <content styleCode="bold">N = 30</content></td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule" valign="top"><content/>Injection site pain </td><td align="center" styleCode="Botrule Rrule" valign="top">8 (27%)</td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule" valign="top">Headache</td><td align="center" styleCode="Botrule Rrule" valign="top">4 (13%)</td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule" valign="top"><content/>Fever (Pyrexia) </td><td align="center" styleCode="Botrule Rrule" valign="top">4 (13%)</td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule" valign="top"><content/>Pain in extremity </td><td align="center" styleCode="Botrule Rrule" valign="top">3 (10%)</td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule" valign="top"><content/>Bruising (hematoma) </td><td align="center" styleCode="Botrule Rrule" valign="top">2 (7%)</td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule" valign="top">Fatigue</td><td align="center" styleCode="Botrule Rrule" valign="top">2 (7%)</td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule" valign="top"><content/>Vomiting </td><td align="center" styleCode="Botrule Rrule" valign="top">2 (7%)</td></tr></tbody></table>
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.